Cipla, Hetero receive drug controller's emergency approval for Remdesivir for severe Covid-19 patients

Remdesivir is an experimental drug from drug maker Gilead that has
shown to bring down the viral load on patients and hence help in
faster discharge. The efficacy of the drug on severe patients is still
under study. US drug maker Gilead has given voluntary licenses to five
Indian companies to manufacture this drug.

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/cipla-hetero-receive-drug-controllers-emergency-approval-for-remdesivir-for-severe-covid-19-patients/articleshow/76485542.cms

Comments

Popular posts from this blog

Clinical Database Management Professional Vacancy @ Teva

Pharma Production Executive Post Vacancy @ Intas

Biotecnika Times – Newsletter 28.02.2020 – DST Women Scientist WOS B, DBT-IOC Recruitment